london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Specific ocular changes in compound heterozygotes TTRVal30Met/TTRThr119Met in familial amyloid polyneuropayhy (FAP) patients

Poster Details

First Author: C.Vale PORTUGAL

Co Author(s):    A. Figueiredo   N. Ferreira   T. Coelho            0   0 0   0 0   0 0   0 0

Abstract Details


to report ocular manifestations in FAP patients that are compound heterozygotes with Val30Met and Thr119Met mutations.


Hospital Santo António (HSA) - Centro Hospitalar do Porto


retrospective observational consecutive case series of 2 FAP patients with two TTR mutations, Val30Met and Thr119Met. Demographic data, age of onset of symptoms, stage of disease, ophthalmologic changes and previous ocular surgeries were evaluated.


Two patients from early onset families, both aged 67 years, one male, with onset of symptoms at 56 years, and one female, with onset at 62 years. Both are in stage 1 and both are on Tafamidis. The two patients had glaucoma, amyloid deposits on anterior lens surface and pupillary border. Some vitreous opacities were present but did not impair fundoscopy nor made vitrectomy required. Scalloped pupil was observed in 3 eyes. The female patient had glaucoma surgery on both eyes.


the presence of the non-pathogenic mutation Thr119Met in carriers of the pathogenic mutation Val30Met has been described as protective. In fact, these two patients had a much later age of onset as compared to their relatives but besides neuropathy they also present eye disease. Therefore, the ophthalmologist has an important role in the follow-up of these compound heterozygous FAP patients.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy